ArcticZymes Technologies ASA

LSE:0DRV Stock Report

Market Cap: NOK 724.2m

ArcticZymes Technologies Valuation

Is 0DRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0DRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
NOK 70.40
Fair Value
79.7% undervalued intrinsic discount
2
Number of Analysts

Below Fair Value: 0DRV (NOK14.3) is trading below our estimate of fair value (NOK70.4)

Significantly Below Fair Value: 0DRV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0DRV?

Key metric: As 0DRV is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0DRV. This is calculated by dividing 0DRV's market cap by their current revenue.
What is 0DRV's PS Ratio?
PS Ratio6.5x
SalesNOK 110.76m
Market CapNOK 724.19m

Price to Sales Ratio vs Peers

How does 0DRV's PS Ratio compare to its peers?

The above table shows the PS ratio for 0DRV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.7x
TRX Tissue Regenix Group
1.6x15.1%UK£42.0m
BVXP Bioventix
12.3xn/aUK£167.0m
PBX ProBiotix Health
5.9xn/aUK£12.7m
VRCI Verici Dx
3x78.8%UK£10.3m
0DRV ArcticZymes Technologies
6.5x14.2%NOK 724.2m

Price-To-Sales vs Peers: 0DRV is expensive based on its Price-To-Sales Ratio (6.5x) compared to the peer average (5.7x).

Price to Sales Ratio vs Industry

How does 0DRV's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.8x3.5%US$1.52b
OXB Oxford Biomedica
4.6x21.2%US$557.10m
TRX Tissue Regenix Group
1.6x15.1%US$52.25m
AREC Arecor Therapeutics
4.5x2.5%US$27.46m
0DRV 6.5xIndustry Avg. 8.6xNo. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0DRV is good value based on its Price-To-Sales Ratio (6.5x) compared to the European Biotechs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is 0DRV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0DRV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0DRV's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0DRV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 14.30
NOK 16.00
+11.9%
6.3%NOK 17.00NOK 15.00n/a2
Jan ’26NOK 13.60
NOK 16.00
+17.6%
6.3%NOK 17.00NOK 15.00n/a2
Dec ’25NOK 13.20
NOK 16.00
+21.2%
6.3%NOK 17.00NOK 15.00n/a2
Oct ’25NOK 17.00
NOK 24.50
+44.1%
6.1%NOK 26.00NOK 23.00n/a2
Sep ’25NOK 18.98
NOK 24.50
+29.1%
6.1%NOK 26.00NOK 23.00n/a2
Aug ’25NOK 25.70
NOK 27.50
+7.0%
9.1%NOK 30.00NOK 25.00n/a2
Jul ’25NOK 25.85
NOK 27.50
+6.4%
9.1%NOK 30.00NOK 25.00n/a2
Jun ’25NOK 24.50
NOK 27.50
+12.2%
9.1%NOK 30.00NOK 25.00n/a2
Analyst Price Target
Consensus Narrative from 2 Analysts
NOK 16.14
Fair Value
11.4% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 10:24
End of Day Share Price 2025/01/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ArcticZymes Technologies ASA is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hans BohnBeringer Finance AB
Mikkel Nyholt-SmedsengCarnegie Investment Bank AB
Espen JørgensenDNB Markets